Moberg Pharma AB is undergoing a strategic shift with the proposed addition of new board members and a withdrawal of share issue authorization, reflecting the company’s confidence in its financial health and commitment to innovation in the pharmaceu…

Moberg Pharma AB reports significant financial decline in Q2 2025, but CEO cites success of flagship product Terclara and strategic focus on European markets as reasons for hope.